Current status and future prospects of peptide-based cancer vaccines

被引：11

作者：

Wada, Satoshi ^{[1
]}

Yada, Erika ^{[1
]}

Ohtake, Junya ^{[1
]}

Fujimoto, Yuki ^{[1
]}

Uchiyama, Hidemi ^{[1
]}

Yoshida, Shintaro ^{[1
]}

Sasada, Tetsuro ^{[1
]}

机构：

[1] Kanagawa Canc Ctr, Res Inst, Div Canc Immunotherapy, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2418515, Japan

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 11期

关键词：

adaptive immunity; adjuvant; cancer immunotherapy; clinical trials; peptide vaccines; T-cell therapy; tumor antigens; CYTOLYTIC T-LYMPHOCYTES; PHASE-II TRIAL; CLINICAL-TRIAL; MULTICENTER TRIAL; IMMUNE-RESPONSES; MIXED PEPTIDES; VACCINATION; GENE; MELANOMA; CELLS;

D O I：

10.2217/imt-2016-0063

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer immunotherapy has attracted attention worldwide owing to the recent development of immune checkpoint inhibitors. However, these therapies have shown limited efficacy, and further advancements are needed before these modalities can progress to widespread use. Immune checkpoint inhibitors are a type of nonspecific cancer immunotherapy, and antitumor effects are only observed when cancer-specific T cells are found within the nonspecifically activated T-cell group. In order to facilitate the development of potent immunotherapies, selective enhancement of cancer-specific T cells is essential. In this report, we discuss current and future perspectives, including the latest clinical trials of cancer-specific immunotherapies, particularly cancer peptide vaccines.

引用

收藏

页码：1321 / 1333

页数：13

相关论文

共 73 条

[1] PEPTIDE-SPECIFIC ACTIVATION OF CYTOLYTIC CD4(+) T-LYMPHOCYTES AGAINST TUMOR-CELLS BEARING MUTATED EPITOPES OF K-RAS P21 [J].

ABRAMS, SI ;

DOBRZANSKI, MJ ;

WELLS, DT ;

STANZIALE, SE ;

ZAREMBA, S ;

MASUELLE, L ;

KANTOR, JA ;

SCHLOM, J .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (09) :2588-2597

[2] A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].

Ambrosini, G ;

Adida, C ;

Altieri, DC .

NATURE MEDICINE, 1997, 3 (08) :917-921

[3] MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100 IS RECOGNIZED BY MELANOMA-DERIVED TUMOR-INFILTRATING LYMPHOCYTES [J].

BAKKER, ABH ;

SCHREURS, MWJ ;

DEBOER, AJ ;

KAWAKAMI, Y ;

ROSENBERG, SA ;

ADEMA, GJ ;

FIGDOR, CG .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :1005-1009

[4] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer [J].

Barve, Minal ;

Bender, James ;

Senzer, Neil ;

Cunningham, Casey ;

Greco, F. Anthony ;

McCune, David ;

Steis, Ronald ;

Khong, Hung ;

Richards, Donald ;

Stephenson, Joe ;

Ganesa, Prasanthi ;

Nemunaitis, Jackie ;

Ishioka, Glenn ;

Pappen, Beena ;

Nemunaitis, Michael ;

Morse, Michael ;

Mills, Bonnie ;

Maples, Phillip B. ;

Sherman, Jeffrey ;

Nemunaitis, John J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) :4418-4425

[5] Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF- and miR23a transfer [J].

Berchem, Guy ;

Noman, Muhammad Zaeem ;

Bosseler, Manon ;

Paggetti, Jerome ;

Baconnais, Sonia ;

Le Cam, Eric ;

Nanbakhsh, Arash ;

Moussay, Etienne ;

Mami-Chouaib, Fathia ;

Janji, Bassam ;

Chouaib, Salem .

ONCOIMMUNOLOGY, 2016, 5 (04)

[6] BAGE - A NEW GENE ENCODING AN ANTIGEN RECOGNIZED ON HUMAN MELANOMAS BY CYTOLYTIC T-LYMPHOCYTES [J].

BOEL, P ;

WILDMANN, C ;

SENSI, ML ;

BRASSEUR, R ;

RENAULD, JC ;

COULIE, P ;

BOON, T ;

VANDERBRUGGEN, P .

IMMUNITY, 1995, 2 (02) :167-175

[7] THE TYROSINASE GENE CODES FOR AN ANTIGEN RECOGNIZED BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES ON HLA-A2 MELANOMAS [J].

BRICHARD, V ;

VANPEL, A ;

WOLFEL, T ;

WOLFEL, C ;

DEPLAEN, E ;

LETHE, B ;

COULIE, P ;

BOON, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :489-495

[8] Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial [J].

Butts, Charles ;

Socinski, Mark A. ;

Mitchell, Paul L. ;

Thatcher, Nick ;

Havel, Libor ;

Krzakowski, Maciej ;

Nawrocki, Sergiusz ;

Ciuleanu, Tudor-Eliade ;

Bosquee, Lionel ;

Manuel Trigo, Jose ;

Spira, Alexander ;

Tremblay, Lise ;

Nyman, Jan ;

Ramlau, Rodryg ;

Wickart-Johansson, Gun ;

Ellis, Peter ;

Gladkov, Oleg ;

Pereira, Jose Rodrigues ;

Eberhardt, Wilfried Ernst Erich ;

Helwig, Christoph ;

Schroeder, Andreas ;

Shepherd, Frances A. .

LANCET ONCOLOGY, 2014, 15 (01) :59-68

[9] Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation [J].

Chaft, Jamie E. ;

Litvak, Anya ;

Arcila, Maria E. ;

Patel, Payal ;

D'Angelo, Sandra P. ;

Krug, Lee M. ;

Rusch, Valerie ;

Mattson, Alicia ;

Coeshott, Claire ;

Park, Bernard ;

Apelian, David M. ;

Kris, Mark G. ;

Azzoli, Christopher G. .

CLINICAL LUNG CANCER, 2014, 15 (06) :405-410

[10] HUMAN PAPILLOMAVIRUS TYPE-16 NUCLEOPROTEIN-E7 IS A TUMOR REJECTION ANTIGEN [J].

CHEN, LP ;

THOMAS, EK ;

HU, SL ;

HELLSTROM, I ;

HELLSTROM, KE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (01) :110-114

← 1 2 3 4 5 6 7 8 →